Kolon Life Science Inc. (KOSDAQ:102940)
South Korea · Delayed Price · Currency is KRW 55,700
-1,300 (-2.28%)
Apr 10, 2026, 3:30 PM KST
Kolon Life Science Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 208,982 | 161,387 | 124,639 | 161,584 | 165,485 |
Other Revenue | -0 | -0 | - | -0 | -0 |
| 208,982 | 161,387 | 124,639 | 161,584 | 165,485 | |
Revenue Growth (YoY) | 29.49% | 29.48% | -22.86% | -2.36% | 27.87% |
Cost of Revenue | 153,204 | 144,643 | 112,343 | 124,567 | 128,381 |
Gross Profit | 55,778 | 16,744 | 12,296 | 37,017 | 37,104 |
Selling, General & Admin | 22,736 | 21,131 | 20,149 | 19,581 | 17,696 |
Research & Development | 13,907 | 16,439 | 14,892 | 13,583 | 14,327 |
Amortization of Goodwill & Intangibles | 116.05 | 166.77 | 131.45 | 157.01 | 166.64 |
Other Operating Expenses | 353.78 | 231.77 | 242.57 | 198.91 | 207.68 |
Operating Expenses | 38,205 | 38,828 | 36,391 | 34,375 | 32,855 |
Operating Income | 17,572 | -22,084 | -24,095 | 2,642 | 4,249 |
Interest Expense | -7,784 | -7,411 | -5,857 | -3,722 | -6,013 |
Interest & Investment Income | 94.36 | 135.05 | 168.59 | 114.07 | 120.4 |
Currency Exchange Gain (Loss) | -296.48 | 906.21 | -348.04 | -20.33 | 273.77 |
Other Non Operating Income (Expenses) | -12,056 | -57,324 | -312.22 | 7,959 | 1,600 |
EBT Excluding Unusual Items | -2,470 | -85,779 | -30,444 | 6,972 | 230.15 |
Gain (Loss) on Sale of Investments | - | - | -14.53 | -5.18 | 11.07 |
Gain (Loss) on Sale of Assets | -26.52 | -1,013 | -6.9 | -20.9 | 75.12 |
Asset Writedown | -1,434 | -8,855 | -3,133 | -2,822 | -4,327 |
Pretax Income | 25,756 | -93,086 | -33,598 | 4,124 | -4,011 |
Income Tax Expense | 795.76 | - | 1.25 | 107.93 | -2,636 |
Earnings From Continuing Operations | 24,960 | -93,086 | -33,599 | 4,016 | -1,375 |
Earnings From Discontinued Operations | - | - | 2,873 | -1,883 | - |
Net Income | 24,960 | -93,086 | -30,726 | 2,133 | -1,375 |
Net Income to Common | 24,960 | -93,086 | -30,726 | 2,133 | -1,375 |
Shares Outstanding (Basic) | 12 | 12 | 11 | 11 | 11 |
Shares Outstanding (Diluted) | 14 | 12 | 11 | 13 | 11 |
Shares Change (YoY) | 14.58% | 4.65% | -9.69% | 10.85% | - |
EPS (Basic) | 2001.00 | -7794.00 | -2692.37 | 186.96 | -120.61 |
EPS (Diluted) | 1824.00 | -7794.00 | -2692.37 | 169.00 | -121.00 |
Free Cash Flow | -28,055 | -22,279 | -35,009 | -27,159 | -20,600 |
Free Cash Flow Per Share | -2050.16 | -1865.41 | -3067.66 | -2149.14 | -1807.01 |
Gross Margin | 26.69% | 10.38% | 9.87% | 22.91% | 22.42% |
Operating Margin | 8.41% | -13.68% | -19.33% | 1.64% | 2.57% |
Profit Margin | 11.94% | -57.68% | -24.65% | 1.32% | -0.83% |
Free Cash Flow Margin | -13.43% | -13.80% | -28.09% | -16.81% | -12.45% |
EBITDA | 27,335 | -13,209 | -15,264 | 12,109 | 15,549 |
EBITDA Margin | 13.08% | -8.18% | -12.25% | 7.49% | 9.40% |
D&A For EBITDA | 9,763 | 8,876 | 8,831 | 9,467 | 11,299 |
EBIT | 17,572 | -22,084 | -24,095 | 2,642 | 4,249 |
EBIT Margin | 8.41% | -13.68% | -19.33% | 1.64% | 2.57% |
Effective Tax Rate | 3.09% | - | - | 2.62% | - |
Advertising Expenses | 389.06 | 409.3 | 153.71 | 30 | 0.82 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.